Clinical trial · Interventional
Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer
Phase II Randomized Trial of Prophylactic Manuka Honey for the Reduction of Chemoradiation Therapy Induced Esophagitis-Related Pain During the Treatment of Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Manuka honey may prevent or reduce esophagitis-related pain caused by chemotherapy and radiation therapy. It is not yet known whether Manuka honey is more effective than standard care in preventing pain. PURPOSE: This randomized phase II clinical trial is studying Manuka honey to see how well it works in preventing esophagitis-related pain in patients receiving chemotherapy and radiation therapy for lung cancer.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Dysphagia | — | UNRESOLVED | — |
| Esophagitis | — | UNRESOLVED | — |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Pain | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Manuka honey in liquid form | Drug | — | UNRESOLVED |
| Manuka honey in lozenge form | Drug | — | UNRESOLVED |
| Standard supportive care | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Supportive Care
- description
- Standard supportive care
- interventionNames
- Drug: Standard supportive care
- type
- EXPERIMENTAL
- label
- Liquid Manuka Honey
- description
- Manuka honey in liquid form
- interventionNames
- Drug: Manuka honey in liquid form
- type
- EXPERIMENTAL
- label
- Lozenge Manuka Honey
- description
- Manuka honey in lozenge form
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Patients being treated with combination chemotherapy (definitive or adjuvant) and radiation therapy once daily for small cell or non-small cell lung cancer (primary population for the trial) * Patients can receive chemoradiotherapy while on a Radiation Therapy Oncology Group (RTOG) lung trial or while not being on a clinical trial * No patients receiving chemoradiotherapy while enrolled on a single institution trial or trials coordinated by other cooperative groups * No patients with metastatic disease * At least 5 cm of the esophagus must be in the 60 Gy isodose volume in 1.6 to 2.0 Gy fractions PATIENT CHARACTERISTICS: * Age 18 and up * Able to swallow thick liquids prior to treatment * Able to speak English or Spanish in order to complete required forms (verbal completion is adequate) * No patients with poorly controlled diabetes * No known hypersensitivity to honey PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No patients who have received prior chemotherapy or radiation therapy * No patients receiving more than once daily treatments * Therapeutic use of honey other than the Manuka honey provided for this trial is not allowed while patients are on study * Patients must also avoid honey-flavored medical products and/or sugary, viscous substances * Amifostine is not permitted
References
Publications (0)
Data not yet available